June 13, 2024 8:58pm
As traders weighed cooling inflation pressures; where are the carrots to keep share pricing appreciating other than “uncle algo and his electronic trading dwarfs”?
My advice: keep opening that portfolio envelope and think a game of monopoly and follow RMi’s interchanges to gain profit moves or recoup losses
I say today what others won't, so you can do what others can't!
Never leave an investor uninformed!
I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
Thursday: The Dow closed DOWN -65.11 points or -0.17%, the S&P closed UP +12.71 points or +0.23% while the Nasdaq closed UP +59.12 points or +0.34%
RegMed Investors’ (RMi) pre-open post: “none, preparing for relatives visit – a lot of work for company!
Henry’omics:
We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes closed mixed enhanced by fresh data showing signs of inflation pressures cooling.
Economic Data Docket: May’s producer price index fell -0.2% from the prior month. Economists polled had expected an increase of 0.1%; after May’s consumer price index rose less than expected last month.
Metrics & Advance/Decline (A/D) Line:
Thursday’s advance/decline line at the open was positive with 19 incliner, 12 decliners and 3 flats; ending with a negative close of 14 incliners, 18 decliners and 3 flats
· the IBB was down -0.36% and the XBI was flat 0.00%
· the VIX down -0.10 point or -0.83% at 11.94
Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:
· June: 4 positive and 5 negative closes
Thursday’s Closing Down (10 of 18):
- Ultragenyx Pharmaceuticals (RARE -$1.62 after Wednesday’s +$3.24, Tuesday’s -$0.57 and Monday’s +$0.57),
- BioLife Solutions (BLFS -$1.23),
- Agenus (AGEN -$0.92),
- Beam Therapeutics (BEAM -$0.82 after Wednesday’s +$1.81, Tuesday’s +$0.46 and Monday’s +$1.19)
- Editas Medicine (EDIT -$0.55 after Wednesday’s +$0.61 and Tuesday’s +$0.11),
- Ionis Pharmaceuticals (IONS -$0.38 after Wednesday’s +$1.81, Tuesday’s -$0.10 and Monday’s +$0.84),
- MiMedx (MDXG -$0.25),
- AxoGen (AXGN -$0.23 after Wednesday’s +$0.68 and Tuesday’s +$0.38),
- Vericel (VCEL -$0.17),
- Lenz Therapeutics (LENZ -$0.08 after Wednesday’s -$0.26, Tuesday’s +$1.18 and Monday’s +$2.21),
Flat (3):
- Harvard Apparatus RT (OTCQB: HRGN $0.00 after Wednesday’s -$0.40, Tuesday’s -$0.07 and Monday’s $0.00)
- Bellicum Pharmaceuticals (BLCM) – dropped)
- Homology Medicine (FIXX) – under $1.00
Thursday’s Closing Up (10 of 14):
- Alnylam Pharmaceuticals (ALNY +$1.01 after Wednesday’s +$2.61, Tuesday’s +$2.96 and Monday’s +$0.69)
- Sage Therapeutics (SAGE +$0.65),
- Solid Biosciences (SLDB +$0.58),
- CRISPR Therapeutics (CRSP +$0.43 after Wednesday’s +$2.52, Tuesday’s +$2.32 and Monday’s +$2.12),
- Blueprint Medicine (BPMC +$0.25 after Wednesday’s +$0.75 after Tuesday’s +$1.36),
- Adverum Biotechnologies (ADVM +$0.22 after Wednesday’s +$0.56, Tuesday’s -$0.19),
- Prime Medicine (PRME +$0.22),
- Voyager Therapeutics (VYGR +$0.13),
- Generation Bio (GBIO +$0.12),
- Mesoblast (MESO +$0.11 after Wednesday’s -$0.11 and Tuesday’s +$0.11),
The BOTTOM LINE: Check under the hood, the engine is smoking needing oil as a lubricant
2nd week of June, 4th session … the cell and gene therapy sector experienced another negative close on Thursday after Wednesday ascended positively as Tuesday drifted lower, retreating from Monday’s highs.
· Last week: the cell and gene therapy sector, ended Friday and Thursday ended in the toilet after Wednesday’s positive close Tuesday negative close following Monday’s positive close.
Reiterating, “Net-net I am still expecting a bumpy ride for US equities as we stride through the month of June.”
· The windsock was strong however … as I stated yesterday, Wednesday -the wind or breeze are fleeting … as I perceive a mild correction in the atmosphere.
The top three (3) performing in the session:
· Thursday: Alnylam Pharmaceuticals (ALNY), Sage Therapeutics (SAGE) and Solid Biosciences (SLDB)
· Wednesday: Ultragenyx Pharmaceuticals (RARE), Alnylam Pharmaceuticals (ALNY) and CRISPR Therapeutics (CRSP)
· Tuesday: Alnylam Pharmaceuticals (ALNY), CRISPR Therapeutics (CRSP) and Blueprint Medicine (BPMC)
· Monday: Lenz Therapeutics (LENZ), CRISPR Therapeutics (CRSP) and BioLife Solutions (BLFS)
The worst three (3) in the session:
· Thursday: Ultragenyx Pharmaceuticals (RARE), BioLife Solutions (BLFS) and Agenus (AGEN)
· Wednesday: Regenxbio (RGNX), Harvard Apparatus RT (OTCQB: HRGN) and Lenz Therapeutics (LENZ)
· Tuesday: Ultragenyx Pharmaceuticals (RARE), Agenus (AGEN) and Solid Biosciences (SLDB)
· Monday: Vericel (VCEL), Regenxbio (RGNX) and Solid Biosciences (SLDB)
Welcome to my world of defining the “grey’ in our universe!
· Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.
I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
